[go: up one dir, main page]

DE60315664D1 - Verfahren zur herstellung von 5-(1,3-oxazol-2-yl)benzoesäurederivaten - Google Patents

Verfahren zur herstellung von 5-(1,3-oxazol-2-yl)benzoesäurederivaten

Info

Publication number
DE60315664D1
DE60315664D1 DE60315664T DE60315664T DE60315664D1 DE 60315664 D1 DE60315664 D1 DE 60315664D1 DE 60315664 T DE60315664 T DE 60315664T DE 60315664 T DE60315664 T DE 60315664T DE 60315664 D1 DE60315664 D1 DE 60315664D1
Authority
DE
Germany
Prior art keywords
sub
oxazol
preparing
benzoic acid
acid derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60315664T
Other languages
English (en)
Inventor
Michael R Reeder
Rick J Imbordino
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia and Upjohn Co LLC
Original Assignee
Pharmacia and Upjohn Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia and Upjohn Co LLC filed Critical Pharmacia and Upjohn Co LLC
Application granted granted Critical
Publication of DE60315664D1 publication Critical patent/DE60315664D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Psychiatry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Catalysts (AREA)
DE60315664T 2002-06-20 2003-06-20 Verfahren zur herstellung von 5-(1,3-oxazol-2-yl)benzoesäurederivaten Expired - Lifetime DE60315664D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39028502P 2002-06-20 2002-06-20
US45047803P 2003-02-27 2003-02-27
PCT/US2003/019585 WO2004000821A1 (en) 2002-06-20 2003-06-20 Process for preparing 5-(1, 3-oxazol-2-yl) benzoic acid derivatives

Publications (1)

Publication Number Publication Date
DE60315664D1 true DE60315664D1 (de) 2007-09-27

Family

ID=30003150

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60315664T Expired - Lifetime DE60315664D1 (de) 2002-06-20 2003-06-20 Verfahren zur herstellung von 5-(1,3-oxazol-2-yl)benzoesäurederivaten

Country Status (17)

Country Link
US (2) US7115747B2 (de)
EP (1) EP1532123B1 (de)
JP (1) JP2005533811A (de)
CN (1) CN1324017C (de)
AT (1) ATE370131T1 (de)
AU (1) AU2003249344A1 (de)
BR (1) BR0312439A (de)
CA (1) CA2489988A1 (de)
CO (1) CO5670350A2 (de)
DE (1) DE60315664D1 (de)
EA (1) EA008389B1 (de)
IL (1) IL165763A0 (de)
MX (1) MXPA04012630A (de)
NO (1) NO20045497L (de)
NZ (1) NZ537390A (de)
PL (1) PL374999A1 (de)
WO (1) WO2004000821A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004050609A1 (en) * 2002-11-27 2004-06-17 Elan Pharmaceutical, Inc. Substituted ureas and carbamates
TW200738701A (en) 2005-07-26 2007-10-16 Du Pont Fungicidal carboxamides
WO2007061670A1 (en) 2005-11-21 2007-05-31 Amgen Inc. Beta-secretase modulators and methods of use
US7745484B2 (en) * 2005-11-21 2010-06-29 Amgen Inc. Beta-secretase modulators and methods of use
US7838676B2 (en) 2005-11-21 2010-11-23 Amgen Inc. Beta-secretase modulators and methods of use
US7872009B2 (en) * 2005-11-21 2011-01-18 Amgen Inc. Beta-Secretase modulators and methods of use
US20080277393A1 (en) * 2007-05-07 2008-11-13 True Charles W Collapsible, stackable, semi-rigid universal cotainer for hazardous and non-hazardous goods
TW200901991A (en) 2007-05-25 2009-01-16 Amgen Inc Substituted hydroxyethyl amine compounds as beta-secretase modulators and methods of use
CA2687608C (en) * 2007-05-25 2013-07-02 Amgen Inc. Substituted hydroxyethyl amine compounds as beta-secretase modulators and methods of use
US7803809B2 (en) 2008-11-12 2010-09-28 Amgen Inc. Substituted pyrano [2,3-b] pyridinamine compounds as beta-secretase modulators and methods of use
MX2011002705A (es) 2008-09-11 2011-09-09 Amgen Inc Compuestos con anillos espiro-triciclicos como moduladores de beta-secretasas y metodos de uso.
US9296698B2 (en) 2009-11-23 2016-03-29 Amgen Inc. Amino heteroaryl compounds as beta-secretase modulators and methods of use
EP2504330A1 (de) 2009-11-23 2012-10-03 Amgen Inc. Aminoheteroarylverbindungen als beta-sekretase-modulatoren und verwendungsverfahren dafür
CA2788363A1 (en) 2010-01-19 2011-07-28 Amgen Inc. Amino heteroaryl compounds as beta-secretase modulators and methods of use
MX2012010658A (es) 2010-03-15 2012-12-05 Amgen Inc Compuestos de anillo espiro tetraciclico como moduladores de beta-secretasa.
ES2450568T3 (es) 2010-03-15 2014-03-25 Amgen Inc. Compuestos espiero de amino-dihidrooxazina y amino-dihidrotiazina como moduladores de beta-secretasa y su uso médico
WO2012109165A1 (en) 2011-02-07 2012-08-16 Amgen Inc. 5-amino-oxazepine and 5-amino-thiazepane compounds as beta-secretase antagonists and methods of use
WO2013044092A1 (en) 2011-09-21 2013-03-28 Amgen Inc. Amino-oxazines and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use
US9725469B2 (en) 2012-11-15 2017-08-08 Amgen, Inc. Amino-oxazine and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use
US9462841B1 (en) 2016-03-01 2016-10-11 William Popejoy Protective headgear and shoulder pad apparatus and methods
US11272751B2 (en) 2016-03-01 2022-03-15 Nicholas Popejoy Protective headgear, impact diffusing systems and methods

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20020276A1 (es) * 2000-06-30 2002-04-06 Elan Pharm Inc COMPUESTOS DE AMINA SUSTITUIDA COMO INHIBIDORES DE ß-SECRETASA PARA EL TRATAMIENTO DE ALZHEIMER
MXPA04003245A (es) * 2001-10-04 2004-08-11 Elan Pharm Inc Hidroxipropilaminas.
EA200400648A1 (ru) * 2001-11-08 2005-04-28 Элан Фармасьютикалз, Инк. N, n'-замещенные производные 1,3-диамино-2-гидроксипропана
GB0325830D0 (en) * 2003-11-05 2003-12-10 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
ATE370131T1 (de) 2007-09-15
BR0312439A (pt) 2005-05-10
CN1324017C (zh) 2007-07-04
AU2003249344A1 (en) 2004-01-06
NO20045497L (no) 2005-03-07
EA008389B1 (ru) 2007-04-27
PL374999A1 (en) 2005-11-14
EP1532123A1 (de) 2005-05-25
WO2004000821A1 (en) 2003-12-31
NZ537390A (en) 2006-07-28
MXPA04012630A (es) 2005-09-30
HK1081543A1 (zh) 2006-05-19
US7115747B2 (en) 2006-10-03
JP2005533811A (ja) 2005-11-10
CA2489988A1 (en) 2003-12-31
IL165763A0 (en) 2006-01-15
US20070105921A1 (en) 2007-05-10
EA200401510A1 (ru) 2005-06-30
CN1662510A (zh) 2005-08-31
US20040063965A1 (en) 2004-04-01
NO20045497D0 (no) 2004-12-16
CO5670350A2 (es) 2006-08-31
EP1532123B1 (de) 2007-08-15

Similar Documents

Publication Publication Date Title
DE60315664D1 (de) Verfahren zur herstellung von 5-(1,3-oxazol-2-yl)benzoesäurederivaten
ATE450523T1 (de) Verfahren zur herstellung von 3-halogen-4,5- dihydro-1 h-pyrazolen
JP2005502658A5 (de)
ATE404637T1 (de) Verbessertes verfahren und methode zur herstellung von asymmetrischen monofunktionalisierten indocyaninmarkern sowie erhaltene verbindungen
ATE348814T1 (de) Verfahren zur herstellung von chinolinderivaten
ATE331713T1 (de) Verfahren zur herstellung von 5-nitrobenzofuranen
DE602004011255D1 (de) Phosphinsäurederivate, inhibitoren von beta-sekretase zur behandlung von alzheimer-krankheit
ATE332304T1 (de) Cefdinir salze als zwischenprodukte
DE502004004970D1 (de) Verfahren zur herstellung von oh-geschützten ä4-(2,6-diamino-9h-purin-9-yl)-1,3-dioxolan-2-ylümethanol-derivaten
ATE531702T1 (de) Verfahren zur herstellung von epoxytriazolderivat und zwischenprodukten dafür
DE602006021411D1 (de) Verfahren zur herstellung von optional 2-substituierten 1,6-dihydro-6-oxo-4-pyrimidincarboxylsäuren
ATE157647T1 (de) Verfahren zur herstellung von alpha- ketoamidderivaten
ATE496907T1 (de) Verfahren zur herstellung von cilostazol
DE502005008867D1 (de) Verfahren zur herstellung von 2,5-dimethylphenylessigsäure
ATE415404T1 (de) Lösungsmittelfreies verfahren zur herstellung von diketopyrrolopyrrol-derivaten
ATE437855T1 (de) (4,5,6,7-tetrahydro-1h-indol-7- yl)essigsäurederivate zur behandlung von alzheimer-krankheit
ATE282594T1 (de) Verfahren zur herstellung von (+)-trans-4-p- fluorophenyl-3-hydroxymethyl-1-methylpiperidin
ATE390400T1 (de) Verfahren zur herstellung von alpha'-chlorketonen
DE60306361D1 (de) Verfahren zur herstellung von benazeprilhydrochloride
ATE339401T1 (de) Verfahren zur herstellung von alpha-(3-arylthio)- acetophenonen
WO2004032854A3 (en) Pharmaceutical compositions for treatment of parkinson's disease
DE60226879D1 (de) Verfahren zur herstellung von 4-(imidazol-1-yl)benzolsulfonamidderivaten
ATE223377T1 (de) Verfahren zur herstellung von difluoracetophenon- derivaten
DE602005022213D1 (de) Verfahren zur herstellung von phenyl-2-pyrimidinyl-ketonen und neuen zwischenprodukten daraus
DE60225338D1 (de) Verfahren zur herstellung von derivaten von 3,3-dimethyl-2-formylcyclopropanekarbonsäure

Legal Events

Date Code Title Description
8332 No legal effect for de